Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12035965 | 0.99 | ADORA1 (0.46) | ADORA1GRAMD1AF10P2RX3FABP4 | |
| SCHEMBL210375 | 0.88 | ADORA1 (0.54) | ADORA1GRAMD1AF10P2RX3FABP4 | |
| SCHEMBL741444 | 0.87 | ADORA1 (0.55) | ADORA1GRAMD1AF10P2RX3FABP4 | |
| Lithium Ion SCHEMBL1504295 | 0.85 | ADORA1 (0.39) | ADORA1GRAMD1AF10P2RX3MAPT | |
| SCHEMBL26092447 | 0.82 | ADORA1 (0.51) | ADORA1GRAMD1AP2RX3KDM4ESMN1; SMN2 | |
| SCHEMBL741730 | 0.82 | ADORA1 (0.42) | ADORA1GRAMD1AP2RX3ESR2MAPT | |
| SCHEMBL741852 | 0.81 | ADORA1 (0.47) | ADORA1GRAMD1AP2RX3MAPTKDM4E | |
| SCHEMBL16794209 | 0.80 | ADORA1 (0.47) | ADORA1GRAMD1AF10FABP4FABP5 | |
| SCHEMBL26094092 | 0.78 | ADORA1 (0.40) | ADORA1GRAMD1AP2RX3MAPTKDM4E | |
| SCHEMBL743524 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| CN-1826333-B | Diamine derivatives | DAIICHI SANKYO CO LTD | 2012-12-26 | — | — | CN | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| CN-1894238-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2007-01-10 | — | — | CN | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| CN-1826333-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-08-30 | — | — | CN | disclosed |
| CN-1751025-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-03-22 | — | — | CN | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | ADORA1 2074/4885GRAMD1A 2501/4885F10 152/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | ADORA1 1535/4885GRAMD1A 2645/4885F10 9/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | ADORA1 1667/4885GRAMD1A 2556/4885F10 196/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | ADORA1 1667/4885GRAMD1A 2556/4885F10 196/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | ADORA1 1479/4885GRAMD1A 2525/4885F10 72/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | ADORA1 665/4885GRAMD1A 3671/4885F10 127/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | ADORA1 1667/4885GRAMD1A 2556/4885F10 196/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | ADORA1 486/4885GRAMD1A 3853/4885F10 4/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | ADORA1 1864/4885GRAMD1A 2404/4885F10 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.